@article{3102824,
    title = "Safety and efficacy of pirfenidone and nintedanib in patients with idiopathic pulmonary fibrosis and carrying a telomere-related gene mutation",
    author = "Justet, A. and Klay, D. and Porcher, R. and Cottin, V. and Ahmad, K. and Molina, M.M. and Nunes, H. and Reynaud-Gaubert, M. and Naccache, J.M. and Manali, E. and Froidure, A. and Jouneau, S. and Wemeau, L. and Andrejak, C. and Gondouin, A. and Hirschi, S. and Blanchard, E. and Bondue1, B. and Bonniaud, P. and Tromeur, C. and Prévot, G. and Marchand-Adam, S. and Funke-Chambour, M. and Gamez, A.S. and Ba, I. and Papiris, S. and Grutters, J. and Crestani, B. and Van Moorsel, C. and Kannengiesser, C.",
    journal = "European Respiratory Journal",
    year = "2021",
    volume = "57",
    number = "2",
    publisher = "European Respiratory Society",
    issn = "0903-1936, 1399-3003",
    doi = "10.1183/13993003.03198-2020",
    keywords = "dyskerin;  nintedanib;  pirfenidone;  telomerase reverse transcriptase;  dipyrone;  indole derivative;  nintedanib;  pirfenidone, age;  antifibrotic therapy;  Belgium;  confounding variable;  demography;  diffusing capacity for carbon monoxide;  disease exacerbation;  disease severity;  drug efficacy;  drug safety;  drug withdrawal;  fibrosing alveolitis;  follow up;  forced vital capacity;  gastrointestinal disease;  gene;  gene mutation;  genetic variability;  Greece;  human;  hypertransaminasemia;  Letter;  lung fibrosis;  lung function test;  lung transplantation;  multidisciplinary team;  Netherlands;  PARN gene;  people by smoking status;  prediction;  respiratory failure;  RTEL1 gene;  self report;  skin manifestation;  Spain;  Switzerland;  telomere;  TERC gene;  TERT gene;  treatment withdrawal;  fibrosing alveolitis;  genetics;  mutation;  treatment outcome, Humans;  Idiopathic Pulmonary Fibrosis;  Indoles;  Mutation;  Pyridones;  Telomere;  Treatment Outcome"
}